Drug
Nelarabine clinical trials
Also written Arranon and 506U78.
- studies test it
- 25
- open now
- 5
- in phase 3
- 4
- first study started
- 1997
Keep track of what changes. Save the nelarabine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Arranon
- 14
Development codes
Studies by the year they started
25 studies that test it; most in 2000 (4)
| Year | Studies |
|---|---|
| 1997 | 1 |
| 1998 | 1 |
| 1999 | 3 |
| 2000 | 4 |
| 2001 | 1 |
| 2003 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2010 | 3 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2024 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 16
- Phase 3
- 4
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
- Lymphoma
- 10
Who runs them
Industry 3 · Other 22
National Cancer Institute (NCI) (8) · St. Jude Children's Research Hospital (2) · Goethe University (2) · M.D. Anderson Cancer Center (2) · GlaxoSmithKline (2) · University College, London (1) · Emory University (1) · SWOG Cancer Research Network (1)
Often tested with
Tested in the same studies.
Cyclophosphamide (5) · Etoposide (4) · Pegaspargase (3) · Cytarabine (3) · Methotrexate (3) · Bortezomib (3) · Daunorubicin (2) · Mercaptopurine (2)
Studies
Open first, then newest update. How each study uses nelarabine is read from its arms, and is right about nine times in ten.
Testing it · 25
- Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT00501826Written as Nelarabine
- Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)RecruitingPhase 2St. Jude Children's Research HospitalNCT06390319Written as Nelarabine
- Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)Not yet recruitingPhase 2/3Children's Oncology GroupNCT07072585Written as Nelarabine
- The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic LymphomaNot yet recruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06434467Written as Nelarabine injection
- Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old)RecruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT02619630Written as nelarabine
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaActive, not recruitingPhase 2/3St. Jude Children's Research HospitalNCT03117751Written as Nelarabine
- Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified TreatmentCompletedPhase 3Goethe UniversityNCT02881086Written as Nelarabine
- Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedUniversity College, LondonNCT01085617Written as nelarabine
- Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)WithdrawnPhase 2National Cancer Institute (NCI)NCT06210750Written as Nelarabine
- BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic LymphomaTerminatedPhase 2Washington University School of MedicineNCT02763384Written as Nelarabine
- Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/LymphomaCompletedPhase 1Emory UniversityNCT03328104Written as Nelarabine
- 506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL)CompletedPhase 2Goethe UniversityNCT00684619Written as Nelarabine
- Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LLTerminatedPhase 1/2Therapeutic Advances in Childhood Leukemia ConsortiumNCT00981799Written as Nelarabine
- Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid MalignanciesCompletedPhase 1M.D. Anderson Cancer CenterNCT01094860Written as Nelarabine
- Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or LymphomaCompletedPhase 1GlaxoSmithKlineNCT00406757Written as Nelarabine injection 400mg/m2
- 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver ImpairmentTerminatedPhase 1Alliance for Clinical Trials in OncologyNCT00004239Written as Compound 506U78
- S0010 506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic LeukemiaCompletedPhase 2SWOG Cancer Research NetworkNCT00006020Written as nelarabine
- 506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating AgentsCompletedPhase 2GlaxoSmithKlineNCT00003635Written as nelarabine
- 506U78 in Treating Patients With Refractory Hematologic CancerCompletedPhase 2National Cancer Institute (NCI)NCT00002970Written as nelarabine
- 506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaCompletedNot applicableNational Cancer Institute (NCI)NCT00003837Written as nelarabine
See all 25 studies that test nelarabine →
Given in every arm · 3 — nelarabine is usual care beside what is tested
- CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBLRecruitingPhase 1/2University of ChicagoNCT07294677Written as Nelarabine
- Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic LeukemiaTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT03808610Written as Nelarabine
- Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or LymphomaTerminatedPhase 2St. Jude Children's Research HospitalNCT02518750Written as Nelarabine
As the comparator · 2 — what is tested is compared with nelarabine
- Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and AdolescentsActive, not recruitingPhase 3Dana-Farber Cancer InstituteNCT03020030Written as NELARABINE
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaCompletedPhase 3National Cancer Institute (NCI)NCT00408005Written as Nelarabine
Codes
What other systems call nelarabine · ClinicalTrials.gg INT003967
- MeSH (NLM) C104457nelarabineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 60158CV180NELARABINEConfirmed FDA, NLM, Wikidata
- RxNorm 274771Confirmed FDA, Wikidata
- Wikidata Q1216264nelarabineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1704NelarabineOne source FDA
- DrugBank DB01280One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C104457 | nelarabine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 60158CV180 | NELARABINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 274771 | — | Confirmed FDA, Wikidata |
| Wikidata | Q1216264 | nelarabine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1704 | Nelarabine | One source FDA |
| DrugBank | DB01280 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.